Breast cancer is a global health concern accounting for nearly 40 000 deaths each year in the United States alone (1) . Novel strategies for prevention of breast cancer are needed to reduce morbidity and mortality associated with this disease. Primary prevention of breast cancer is feasible as exemplified by successful clinical application of selective estrogen receptor modulators (eg, tamoxifen and raloxifene) and aromatase inhibitors (eg, exemestane) (2) (3) (4) . Unfortunately, women with estrogen receptor-negative breast cancer and a subset of women with estrogen receptor-positive breast cancer are not responsive to these endocrine modalities, which also have side effects (2, 3, 5, 6) . For example, combined analysis of multiple randomized and controlled trials comparing aromatase inhibitors with tamoxifen revealed higher incidence of grade 3 and 4 cardiovascular events resulting from aromatase inhibitor use (5, 6) .
Recent literature highlights the merit of plants used in Ayurvedic medicine, which has been practiced for centuries in India for the treatment of different disorders, for identification of novel cancer preventive agents (7) . Withania somnifera (also known as ashwagandha) is one such medicinal plant with a variety of known pharmacological effects in experimental models, including anticancer effects (8) (9) (10) (11) (12) (13) (14) . For example, injections of the leaf extract of W somnifera every third day to the tumor site resulted in growth retardation of human fibrosarcoma subcutaneously implanted in athymic mice without any adverse side effects (14) .
The anticancer effect of W somnifera is ascribed to withanolides such as withaferin A (WA) ( Figure 1A ) (15) (16) (17) (18) (19) (20) (21) . For example, WA administration for 14 weeks conferred substantial protection against 7,12-dimethylbenz [a] anthracene-induced oral cancer in hamsters (17) . WA was shown to inhibit growth of human cancer cells in culture and in vivo in association with apoptosis induction (18, 19) . The WA-mediated inhibition of experimental metastasis in mice and invasion/migration in vitro were also demonstrated (22, 23) .
The primary objective of the present study was to determine the efficacy of WA for prevention of breast cancer using a clinically relevant transgenic mouse model. Demonstration of in vivo efficacy as well as safety and elucidation of the mechanisms underlying preventive effect against cancer are essential elements for the clinical development of promising cancer preventive agents. The impetus to determine the preventive effect of WA against breast cancer stemmed from the following observations: 1) viability of cultured human breast cancer cells was inhibited significantly in the presence of pharmacological doses of WA (19, 21, 22) ; 2) WA treatment suppressed several oncogenic pathways (23, 24) ; and 3) WA administration retarded growth of MDA-MB-231 human breast cancer xenografts in athymic mice (19) .
Materials and Methods

Reagents
Sources of reagents are described in the Supplementary Methods (available online). Representative hematoxylin and eosin-stained sections of mammary glands showing ductal carcinoma in situ (DCIS), papillary tumor, and focus of invasive carcinoma around papillary tumor (×50 magnification, scale bars = 400 µm). C) Overall tumor incidence in MMTV-neu mice of the WA treatment group and the control group. The P value was calculated by two-sided Fisher exact test.
D)
Macroscopic tumor burden. Results represent the mean weight of palpable tumors (macroscopic tumors) with a cutoff of ≥.05 g with corresponding 95% confidence intervals (error bars). Statistical significance of differences was determined by two-sided Student t test. E) Microscopic tumor burden (area) of DCIS plus papillary tumors and invasive carcinoma lesions. Results represent the mean areas of DCIS plus papillary tumors and invasive carcinoma with their corresponding 95% confidence intervals (error bars). Statistical significance of differences was determined by two-sided Student t test.
Randomization and WA Administration
Use and care of mice for the study described herein was approved by and consistent with the guidelines of the Institutional Animal Care and Use Committee of the University of Pittsburgh. Fourweek-old female mouse mammary tumor virus-neu (MMTV-neu) transgenic mice (homozygous; strain FVB/N-Tg [MMTV-neu] 202Mul/J) were purchased from the Jackson Laboratory (Bar Harbor, ME). Based on our previous work (25), we estimated that 28 mice per group would provide 80% power to detect a 40% difference in carcinoma incidence between groups at the .05 level of statistical significance. Initially, 60 mice were assigned to either vehicle-treated control arm (n = 30) or the WA treatment arm (n = 30). Four mice from the WA treatment group from one cage surprisingly died within a week after start of the treatment (after 2 or 3 intraperitoneal injections), which was unexpected based on our previous experience with athymic mice (19) . The remaining mouse from this cage was sacrificed. Nevertheless, 10 mice were added to the WA treatment arm to account for this loss in sample size. Details of treatment are provided in the Supplementary Methods (available online). The dose and route of WA treatment were selected from the literature (18, 19) . One mouse from the control group was removed from the study due to excessive body weight loss (final number of evaluable mice in the control group, n = 29). Three mice from the WA treatment group were removed from the study/analysis due to morbidity, injection-related lump, or skin disorder (final number of evaluable mice in the WA treatment group, n = 32). Animal weight was recorded weekly. Mice were killed after 28 weeks of treatment by carbon dioxide euthanasia. Details of tissue collection, sectioning, and hematoxylin and eosin (H&E) staining, as well as pathological characteristics of ductal carcinoma in situ (DCIS), papillary tumors, and invasive carcinoma, are described in the Supplementary Methods (available online).
Immunohistochemical Analysis and Terminal
Deoxynucleotidyl Transferase-Mediated Deoxyuridine-5'-Triphosphate Nick-End Labeling (TUNEL) Assay Immunohistochemical analysis for various proteins and TUNEL assay were performed as described by us previously (26, 27) . Details of immunohistochemistry and TUNEL assay are included in the Supplementary Methods (available online).
Measurement of Complex III and Complex IV Activity
Activity of complex III (coenzyme Q:cytochrome c oxidoreductase or cytochrome bc 1 complex) and complex IV (cytochrome c oxidase) in tumor tissue lysate was measured as described by us previously for cells (21) . Detailed methodology is included in the Supplementary Methods (available online).
Metabolomics
Plasma and tumor samples from eight different mice of each group were randomly selected and outsourced to Metabolon, Inc (Durham, NC) for metabolic profiling. These samples were selected prior to the microscopic analysis of tumor incidence and burden. Details of the sample preparation, platforms used for metabolomics, and data analysis are described in the Supplementary Methods (available online).
Two-Dimensional Gel Electrophoresis and Mass Spectrometry
Tumor tissues from three different mice of each group were randomly selected and used to determine treatment-related protein alterations by two-dimensional gel electrophoresis followed by matrix-assisted laser desorption ionization-time of flight/time of flight (MALDI-TOF/TOF) (Applied Biomics, Hayward, CA) as described by us previously (26, 27) . Similar to metabolic profiling, these samples were selected prior to the microscopic analysis of tumor incidence and burden. Detailed methodology for proteomics and cluster analysis is included in the Supplementary Methods (available online).
Statistical Analyses
All statistical tests were two-sided. Statistical significance of difference in the incidence of mammary tumor and pulmonary metastasis was determined by two-sided Fisher exact test. Statistical significance of differences in other measured variables was determined by two-sided Student t test. All statistical tests were done using GraphPad Prism version 4.03 software (La Jolla, CA). The P values are rounded to the second or third significant digit. Exact P value (no rounding) is shown if it is very close to the .05 level. Difference was considered significant at P less than or equal to .05. 
Effect of WA Treatment on Mammary Cancer Development in MMTV-neu Mice
We used a mouse model (MMTV-neu), which faithfully recapitulates aspects of human disease progression in a subset of women with breast cancer (28) (29) (30) , to determine preventive efficacy of WA. The mean initial and final body weights of the control and WA-treated mice were comparable (results not shown). Pathological features of DCIS, papillary tumor, and invasive carcinoma are shown in Figure 1B . The overall mammary tumor incidence was slightly higher in the WA treatment group (84.38%) compared with the control group (72.41%), but the difference was not statistically significant (P = .35 by Fisher exact test) ( Figure 1C ). On the other hand, mean palpable (macroscopic) tumor weight in the WA treatment group (range = .07-2.87 g) was lower by 50% in comparison with the control group (range = .05-4.51 g) (mean = .89 vs 1.78 g, respectively; difference = -.89 g; 95% confidence interval [CI] = -1.71 g to -.07 g; P = .03 by two-sided Student t test) ( Figure 1D ). The mean tumor weight was calculated from sum of tumor weight in an animal, and the average of tumor weight over all the animals for each group. Furthermore, microscopic examination of the H&E-stained mammary gland sections from each mouse of both groups revealed a decrease in the area (burden) of DCIS plus papillary tumors as well as invasive carcinoma in the WA group compared with the control group ( Figure 1E ). For example, the mean area of invasive carcinoma was lower by 95.14% in the WA Figure 4 . Withaferin A (WA) administration inhibits activity of complex III in the tumor of mouse mammary tumor virus-neu mice. A) Activity of complex III in tumor lysates from mice of the WA treatment group and the control group. Complex III activity was measured using oxidized cytochrome c and ubiquinol as substrates. Results represent mean complex III activity (n = 10) with their 95% confidence intervals (error bars). B) Activity of complex IV in tumor lysates from mice of the WA treatment group and the control group. Complex IV activity was measured using reduced cytochrome c as the substrate. Results represent mean complex IV activity (n = 10) with their 95% confidence intervals (error bars). C) 8-Hydroxy-2′-deoxyguanosine (8-OHdG) level by immunohistochemistry in representative tumors of a mouse from the WA treatment group and the control group. Immunohistochemical staining was performed with anti-8-OHdG antibody and analyzed by nuclear algorithm using Aperio ImageScope software (×200 magnification, scale bars = 100 μm). Bar graph shows mean H-score for 8-OHdG (n = 7) with their 95% confidence intervals (error bars). D) 8-OHdG level by immunohistochemistry in representative normal mammary ducts of a mouse from the WA treatment group and the control group. Immunohistochemical staining was performed with anti-8-OHdG antibody and analyzed by nuclear algorithm using Aperio ImageScope software (×200 magnification, scale bars = 100 μm). Bar graph shows mean H-score for 8-OHdG (n = 7) with their 95% confidence intervals (error bars). Statistical significance of differences was determined by two-sided Student t test (A-D).
group compared with the control group (mean = 3.10 vs 63.77 mm 2 , respectively; difference = -60.67 mm 2 ; 95% CI = -122.50 mm 2 to 1.13 mm 2 ; P = .0536 by two-sided Student t test) ( Figure 1E ). These results indicated that WA administration resulted in inhibition of mammary tumor progression in the MMTV-neu mouse model without any signs of treatment-related toxicity except for the unexpected deaths confined to a single cage and removal of 3 mice from the study/analysis due to morbidity, injection-related lump, or skin sores throughout the body. Figure 2A shows H&E-stained lung sections from two representative mice each of WA group and control group. Incidence of lung metastasis was lower by 72.80% in the WA group in comparison with the control group (mean = 9.38% vs 34.48%, respectively; difference = -25.10%; 95% CI of the difference could not be determined due to low incidence in the WA treatment group [n = 3]; P = .03 by two-sided Fisher exact test) ( Figure 2B ). In contrast, the lung metastasis multiplicity per mouse ( Figure 2C ) or the lung NC) for metabolic profiling. The letters P (purple) and T (purple) represent plasma and tumor, respectively. A red arrow denotes P less than .05, and a green arrow denotes P greater than or equal to .05 and P less than .10. Glycolysis intermediates with significant differences between the WA treatment group and the control group are indicated with red font. Glycolysis-related proteins with significant differences in expression between the WA treatment group and the control group are indicated with green font. Bar graphs represent the mean scaled intensity of the intermediates (n = 8) with their 95% confidence intervals (error bars) acetyl CoA = acetyl coenzyme A; DHAP = dihydroxyacetone phosphate; LDH = lactate dehydrogenase; TPI = triose phosphate isomerase. metastatic tumor area ( Figure 2D ) did not differ between the two groups.
Effect of WA Treatment on Lung Metastasis
Effect of WA Treatment on Tumor Apoptosis
Because the size of the microscopic tumors was rather small in the mammary glands of many mice of the WA treatment group, immunohistochemical analysis was not possible for every sample. Nevertheless, we used randomly selected mammary gland sections from seven mice in each group for immunohistochemical analysis of human epidermal growth factor receptor 2 (HER-2) and proliferation marker proliferating cell nuclear antigen (PCNA) (31) . Expression of HER-2 did not differ statistically significantly between tumors of mice from the WA treatment group and the control group (results not shown). Likewise, the difference in mean H-score for nuclear PCNA expression in the tumors of mice from the WA treatment group and the control group was not statistically significant ( Figure 3A) . The mean number of TUNELpositive cells per high-power field in the tumors of mice from the WA group was higher by 2.14-fold compared with those of the control group (mean = 5.30 vs 2.48 TUNEL-positive cells/highpower field, respectively; difference = 2.82; 95% CI = .40 to 5.25; P = .03 by two-sided Student t test, n = 7) ( Figure 3B ). We next proceeded to determine the in vivo effect of WA administration on formation of new blood vessels (neoangiogenesis) in the tumor because 1) neoangiogenesis is essential for tumor growth as well as metastatic spread (32); and 2) WA was previously shown to inhibit angiogenesis in vitro (33) . The number of CD31-positive blood vessels in the tumors of mice from the WA treatment group and the control group was similar ( Figure 3C ).
Effect of WA Treatment on Tumor Complex III Activity
Molecular circuitry of WA-induced apoptosis in cultured breast cancer cells involves inhibition of complex III of the mitochondrial respiratory chain leading to production of reactive oxygen species and eventual cell death (21) . As shown in Figure 4A , mean complex III activity in tumors from mice in the WA group was lower by 36.79% than in the tumor of mice from the control group (mean = .67 vs 1.06 k/min/mg protein, respectively; difference = -.39; 95% CI = -.62 to -.15; P = .003 by two-sided Student t test; n = 10) ( Figure 4A ). Mean activity of complex IV in the tumors from mice of WA group was also lower by 42.78% than in the tumors of mice from the control group, but the difference was not statistically significant ( Figure 4B ). We performed immunohistochemistry for 8-hydroxy-2′-deoxyguanosine (8-OHdG) levels to assess oxidative stress in the tumor as well as in the normal mammary ducts. The 8-OHdG is a product of oxidatively damaged DNA formed by hydroxyl radicals. The mean H-score for 8-OHdG in the tumors from mice of the WA treatment group was higher by 2.13-fold than in the tumors from mice of the control group, but the difference was not statistically significant due to large data scatter, especially in the WA treatment samples ( Figure 4C ). Nevertheless, a majority of the tumors from mice in the WA treatment group exhibited increased staining for 8-OHdG compared with the tumors from mice in the control group. This trend was not discernible in the normal mammary ducts ( Figure 4D ). In summary, these observations provided in vivo evidence for WA-mediated inhibition of complex III activity.
Metabolic Alterations Associated With Mammary Cancer
Prevention by WA A total of 320 and 328 biochemicals of known identity were detectable in the plasma and tumor tissues, respectively. The WA-mediated mammary cancer prevention was associated with a statistically significant alteration at the P ≤ .05 level in 76 biochemicals in the plasma, with increases observed for 24 metabolites and decreases observed for 52 metabolites. Metabolomics using tumor tissues revealed alterations in 24 biochemicals at the P less than or equal to .05 level (n = 2 increase, n = 22 decrease) upon WA administration. One change that was highly consistent in the plasma and tumor tissues from mice of the WA treatment group compared with those from the control group was a decrease in glucose utilization and glycolysis and tricarboxylic acid (TCA) cycle intermediates. A complete list of the metabolite level differences in the plasma and tumor tissues between mice of the WA treatment group and the control group can be found in Supplementary Table 1 (available online). Figure 5A shows the glycolysis pathway and the changes in glycolysis-related intermediates (biochemicals highlighted with red font in Figure 5A ).
For example, the level of lactate was statistically significantly lower in tumors of WA-treated mice compared with control (mean = .84 vs 1.42 scaled intensity, respectively; difference = -.58; 95% CI = -.90 to -.26; P = .002 by two-sided Student t test; n = 8) ( Figure 5B ). Suppression of sorbitol and lactate in the tumor of WA-treated mice was confirmed by measurement of their levels ( Figure 6, A and B) . NC) for metabolic profiling. The letters P (purple) and T (purple) represent plasma and tumor, respectively. A red arrow denotes P less than .05, and a green arrow denotes P greater than or equal to .05 and P less than .10. TCA cycle intermediates with differences between the WA treatment group and the control group are indicated with red font. TCA cycle-related proteins with differences in expression between the WA treatment group and the control group are indicated with green font. Bar graphs represent the mean scaled intensity of the intermediates (n = 8) with their 95% confidence intervals (error bars). acetyl CoA = acetyl coenzyme A; succinyl CoA = succinyl conenzyme A; succinyl CoA synthase = succinyl coenzyme A synthase. In addition, reduced levels of many TCA cycle intermediates in the plasma or tumor tissue was also found to be associated with WA-mediated mammary cancer prevention ( Figure 7 , A and B; altered metabolites are highlighted with red font in Figure 7A ). 
Discussion
This study demonstrates that a very mild regimen of WA administration involving three intraperitoneal injections per week results in statistically significant inhibition of mammary cancer burden and pulmonary metastasis incidence in the MMTV-neu mouse model. The WA-mediated prevention of mammary cancer is associated with increased apoptosis. This study also provides in vivo confirmation of the previous cellular mechanistic observations (21) . Consistent with in vitro observations in cultured breast cancer cells (21) , the apoptosis induction by WA administration in vivo is associated with a significant decrease in the activity of complex III. Relatively higher levels of 8-OHdG in tumor from WA-treated mice compared with that of control mice further attest to the in vivo contribution of the reactive oxygen species-dependent apoptosis mechanism to the cancer-preventive effect of WA. This study indicates that WA administration inhibits tumor burden but not tumor incidence. A few possibilities deserve attention to explain these results. First, it is possible that inhibition of mammary cancer incidence by WA requires daily administration of the agent rather than the intermittent dosing schedule employed in this study. Second, we have shown recently that WA treatment causes activation of Notch2 and Notch4 in cultured human breast cancer cells (22) . Thus, it is also plausible that the activation of Notch signaling, which is often hyperactive in human breast cancers (34, 35) , impedes preventive efficacy of WA. However, additional work is needed to systematically explore these possibilities.
Increased uptake of glucose and dependence on glycolysis instead of oxidative phosphorylation are biochemical hallmarks of cancer cells initially observed by Otto Warburg several decades ago (36) . Increased glycolysis confers survival advantage to cancer cells and is linked to oncogenic transformation (37, 38) . More recent studies have indicated that hypoxic tumor cells primarily use glucose for glycolytic energy production and release lactic acid that fuels the oxidative metabolism in oxygenated tumor cells (39) . The metabolomic and proteomic results described herein show, for the first time, that mammary cancer prevention by WA is associated with suppression of glycolysis and TCA cycle, at least in the MMTV-neu mice.
Many glycolysis-and TCA cycle-related proteins downregulated in the tumors of WA-treated mice have relevance to breast cancer (40) (41) (42) (43) (44) (45) (46) . For example, fructose-bisphosphate aldolase and glyceraldehyde-3-phosphate dehydrogenase, both of which are significantly downregulated in tumors from WA-treated mice, are overexpressed in ductal carcinoma compared with normal breast tissue (40) . Protein alteration profiling in infiltrating ductal carcinoma of the breast from Tunisian women revealed overexpression of several glycolysis-related enzymes including phosphoglycerate kinase (41) . The tumors from the WA-treated mice show decreased expression of M2-type pyruvate kinase, which is considered an attractive target for cancer therapy (44) . Breast cancer relevance has also been suggested for the TCA cycle-related enzyme isocitrate dehydrogenase (45) , whose expression is significantly decreased in the tumors of WA-treated mice.
Our study has some limitations. First, it is important to determine oral bioavailability of WA as other routes of administrations are not practical for cancer prevention purposes. Second, detailed toxicology of WA is needed to determine its safety in light of unexpected deaths from this group, albeit confined to a single cage. Third, it remains to be determined if the WA-mediated metabolic alterations observed in the present study are unique to the HER-2-driven cancer model. Finally, the functional relevance of other altered proteins in the context of WA-mediated prevention of breast tumor is unclear. 
